Dalton Announces Addition of SEC-MALS Large Molecule Testing Services

Share Article

Dalton adds SEC-MALS large molecule testing capability. This specialized testing capability allows for more accurate measurement of large molecular weight products.

“Having SEC-MALS provides Dalton with a specialized capability that supports large molecule products which are a growing part of our business”

Dalton Pharma Services a leading provider of drug discovery, development and manufacturing services to pharmaceutical and biotechnology companies, today announced that the Company has added SEC-MALS large molecule testing services. The new service addition will allow Dalton to more effectively develop and manufacture large molecules, such as proteins and polymers, for its customers.

Having a new Size Exclusion Chromatography (SEC) - Multi Angle (Laser) Light Scattering (MALS) instrument now allows Dalton to accurately measure size and composition of large molecules. This advanced technology can replace a number of more manual testing methods including viscosity, electrophoresis and chromatography retention times. It provides an absolute measure of molecular weight for molecules 10 to 1,000 nm in size.

Dalton’s scientific team is able to develop and validate new analytical methods using the technology as well as reliably testing and releasing large molecule products by this method.

“Having SEC-MALS provides Dalton with a specialized capability that supports large molecule products which are a growing part of our business”, said Peter Pekos, CEO of Dalton. “We are constantly expanding our service offering to better meet the evolving needs of our customers. This is an example of how Dalton keeps up with the latest technologies in order to deliver the most efficient services.”

About Dalton:
Dalton Chemical Laboratories Inc. o/a Dalton Pharma Services is a Health Canada approved contract pharmaceutical manufacturer that supplies chemistry, analytical and formulation development services to the biotechnology and pharmaceutical industries in the areas of chemistry, medicinal chemistry and fine chemical manufacture. Dalton provides cGMP manufacturing of solid dosage forms and aseptic filling services to its customers at any stage of the regulatory process (Phase I, II, III or commercial). In its modern cGMP facilities, Dalton produces active pharmaceutical ingredients at the gram or kilogram scale. Dalton conducts aseptic fills to produce batches of finished drug product in vials or syringes, either aseptically filled or terminally sterilized, under fully validated conditions. In addition, Dalton’s analytical chemistry laboratory offers method development, validation and ICH stability programs to its clients. Further information can be found at http://www.dalton.com.

For further information, contact:

Peter Pekos
President & CEO
Dalton Pharma Services Inc.
349 Wildcat Road
Toronto, Ontario
Tel: 416-661-2102

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Peter Pekos
Visit website